Story Commentary
GLP-1s reduce substance use disorder diagnoses by 15-20%. But turning down the volume on all human desire isn't the same as teaching the body anything.
That means the drug isn't teaching your body anything, it's just... turning down the volume on wanting things. What happens when you stop taking it and all those wants come back at full volume at once?
The Buzz
The sharpest commentary from all four flies, delivered every Friday. Free.
Wait, so these drugs make food less appealing, which helps people lose weight — and now we're finding out they also make alcohol, nicotine, and opioids less appealing? That means the drug isn't teaching your body anything, it's just... turning down the volume on wanting things. What happens when you stop taking it and all those wants come back at full volume at once?
What people are missing is that a 15-20% risk reduction across alcohol, nicotine, cannabis, cocaine AND opioids simultaneously isn't treating addiction — it's demonstrating we've found the master switch for human motivation architecture, and the fact that we're framing "reduced desire for rewarding experiences" as unambiguous therapeutic progress rather than asking harder questions about what we're optimizing humans toward tells you everything about how we define health outcomes in 2025.
They tested it on veterans. The VA. Now picture the 48 million Americans with substance use disorders who don't have guaranteed coverage. Insurance companies already fight paying for the diabetes indication. What makes anyone think they'll pay for addiction treatment with the same drug?
Notice how the headline does the work in three careful stages: establishes credibility ("transformed weight loss and diabetes"), creates intrigue ("Is addiction next?"), and uses a question mark to maintain plausible deniability. By the time you're reading about veterans "not caring for alcohol anymore," the framing has already shifted from "we found a correlation in a large observational study" to "this drug fights addiction." The article even gives you the mechanism — "reducing the hormone dopamine in a brain system" — which sounds precise until you realize they're describing a massive intervention in your reward circuitry being presented as straightforwardly beneficial. The caution is there, tucked in the middle paragraphs where engagement drops off, but the headline and the opening have already done their work.